Advanced search
Publication Cover
Future Oncology Volume 12, 2016 - Issue 18
Submit an article Journal homepage
1,020
Views
0
CrossRef citations to date
0
Altmetric
Editorial

The ‘nivolution’ in Renal Cell Carcinoma: Behind the Scenes of Clinical Trials

Sebastiano Buti1 Medical Oncology, University Hospital of Parma, ItalyCorrespondence[email protected]
&
Melissa Bersanelli1 Medical Oncology, University Hospital of Parma, Italy
Pages 2061-2063 | Received 21 Jan 2016, Accepted 26 Apr 2016, Published online: 11 May 2016

References

  • McDermott DF , DrakeCG, SznolMet al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J. Clin. Oncol. doi: 10.1200/JCO.58.1041 (2014) ( Epub ahead of print).
  • Motzer RJ , RiniBI, McDermottDFet al. Nivolumab for metastatic renal cell carcinoma: results of a randomized Phase II trial. J. Clin. Oncol.33, 1430–1437 (2015).
  • Motzer RJ , EscudierB, McDermottDFet al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med.373(19), 1803–1813 (2015).
  • Rizvi NA , HellmannMD, SnyderAet al. Cancer immunology: mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science348, 124–128 (2015).
  • Buti S , BersanelliM, SikokisAet al. Chemotherapy in metastatic renal cell carcinoma today? A systematic review. Anticancer Drugs24, 535–554 (2013).
  • Eisenhauer EA , TherasseP, BogaertsJet al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer45(2), 228–247 (2009).
  • Wolchok JD , HoosA, O’DaySet al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res.15(23), 7412–7420 (2009).
  • Motzer RJ , EscudierB, OudardSet al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet372, 449–456 (2008).
  • Motzer RJ , BacikJ, SchwartzLHet al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J. Clin. Oncol.22, 454–463 (2004).
  • Motzer RJ , MazumdarM, BacikJet al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol.17, 2530–2540 (1999).
  • Heng DYC , XieW, ReganMMet al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol.27, 5794–5799 (2009).
  • Herbst RS , SoriaJC, KowanetzMet al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature515, 563–567 (2014).
  • Motzer RJ , SharmaP, McDermottDFet al. CheckMate 025 Phase III trial: outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC). J. Clin. Oncol.34(Suppl. 2S), Abstract 498 (2016).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.